WNTinib_product_DataBase

Bioactivity	WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation[1].
Invitro	WNTinib (1μM; 3 days) 在 CTNNB1 突变模型中诱导细胞凋亡[1]。WNTinib (0-30 μM; 1 h) 抑制 HEPG2 细胞中的 pEZH2 水平[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> WNTinib 相关抗体: Western Blot Analysis[1] Cell Line:
In Vivo	WNTinib (20mg/kg；口服；0-24 h) 的半衰期为 9.38 小时，口服给药后24小时血浆浓度为 7 μM 并且给药后 72 小时血浆中可检测到的药物量[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	2770091-44-4
Formula	C22H16F6N4O3
Molar Mass	498.38
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Rialdi A, et al. WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Nat Cancer. 2023 Aug;4(8):1157-1175.

PeptideDB